CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report August 28, 1996
CHEUNG LABORATORIES, INC.
MARYLAND
2-93826-W 52-1256615
(Commission File Number) (IRS Employer Identification Number)
10220 Old Columbia Road Suite I Columbia, MD 21046
(410) 290-5390
<PAGE>
August 28, 1996
Securities & Exchange Commission
Corporate Finance Division
Chief Counsel's Office
450 Fifth Street, N.W.
Washington, DC 20549-1007
RE: Cheung Laboratories, Inc.
SEC File No. 2-93826-W
Dear Sir or Madam:
Enclosed is a Form 8K for Cheung Laboratories, Inc.
Should you have any questions, please give us a call.
Very truly yours,
Augustine Y. Cheung
President
AYC/dgl
Enclosures
<PAGE>
ITEM 5: OTHER EVENTS
Cheung Laboratories, Inc. (the "Registrant') has entered into an
exclusive license agreement for the commercialization rights to a
patented technology for the treatment of symptomatic problems
associated with prostatic diseases. This technology is expected
to be used in conjunction with the Registrant s current line of
prostatic microwave hyperthermia systems.
This technology is a bi-modal approach which combines heat with
compression of walls of the prostatic urethra to achieve better
treatment result. The bi-modal treatment can be administered on
an out-patient basis. The registrant believes this patented
technology has the potential to shorten the treatment time and
lower the treatment temperature, thus resulting in a safer and
more patient-friendly BPH treatment. Preclinical evaluation
results using this new technology are encouraging.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf of the undersigned thereunto duly authorized.
CHEUNG LABORATORIES, INC.
Date: August 28, 1996 By:______________________________
Dr. Augustine Y. Cheung, President
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K